SCHEMBL2866812

SCHEMBL2866812

COc1ccc(Cn2c(=O)c3c(N)n(-c4ccc(Oc5ccccc5)cc4C)nc3c3ccccc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 1/20 0.44
BLM P54132 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 4/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
RECQL P46063 1/20 0.42
LMNA P02545 2/20 0.41
POLB P06746 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
TP53 P04637 1/20 0.40
GABRA5 P31644 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 3/20 0.39
HDAC1 Q13547 1/20 0.39
THRB P10828 1/20 0.39
EDNRB P24530 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2855985 0.92 P2RX4 (0.43) P2RX4BLMSMN1; SMN2ALDH1A1KMT2A
SCHEMBL2862981 0.90 PLA2G10 (0.39) BLMSMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL2862282 0.89 P2RX4 (0.42) P2RX4BLMSMN1; SMN2ALDH1A1KMT2A
SCHEMBL2864310 0.87 ALDH1A1 (0.37) BLMSMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL2861651 0.87 P2RX4 (0.48) P2RX4BLMSMN1; SMN2ALDH1A1KMT2A
SCHEMBL2861317 0.85 P2RX4 (0.47) P2RX4BLMSMN1; SMN2ALDH1A1KMT2A
SCHEMBL2861755 0.83 P2RX4 (0.48) P2RX4BLMSMN1; SMN2ALDH1A1KMT2A
SCHEMBL2868708 0.83 P2RX4 (0.48) P2RX4BLMSMN1; SMN2ALDH1A1KMT2A
SCHEMBL2861360 0.83 P2RX4 (0.50) P2RX4BLMSMN1; SMN2ALDH1A1KMT2A
SCHEMBL2857612 0.83 P2RX4 (0.50) P2RX4BLMSMN1; SMN2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 P2RX4 718/4885BLM 2899/4885SMN1; SMN2 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.